Skip to content

Author

C. Karaçin

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Pathway-integrated genomic analysis of papillary renal cell carcinoma in the WHO 2022 era: cell cycle pathway alterations as an independent adverse prognostic marker-a dual-cohort study

Aims: The 2022 WHO Classification of Renal Tumors introduced molecularly defined entities within papillary renal cell carcinoma (pRCC), removing the historical type 1/type 2 distinction. The independent prognostic significance of these entities and pathway-level alterations in this revised framework remains incompletel...

Elif Sertesen Çamöz, C. Karaçin · 0 citations
Open access Oct 2026

Distinct NGS mutational landscape and prognostic implications in early-onset colorectal cancer: A dual-cohort analysis of TCGA PanCancer Atlas and MSK-IMPACT 50K

Background Early-onset colorectal cancer (EOCRC), defined as CRC diagnosed before age 50, is rising globally. The genomic landscape of EOCRC has been characterized in several prior studies, but the reproducibility of findings across independent cohorts, the impact of adjustment for tumor stage and sample type, and the...

Elif Sertesen Çamöz, Osman Bilge Kaya, Hakan Erçelebi et al. · 0 citations
Open access 2026

Integrated pathway analysis of small cell lung cancer: NOTCH alterations as an independent favorable prognostic factor and DNA damage repair alterations as correlates of tumor mutational burden

NotCH alterations serve as an independent favorable prognostic marker, while DDR alterations associate with elevated TMB without independent prognostic impact, and these findings validate NOTCH as a prognostic biomarker in SCLC and support pathway-level genomic assessment in clinical risk stratification.

E. Camoz, C. Karaçin · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.